Biomarkers in a Cohort of HIV-Infected Patients Single- or Co-Infected with HTLV-1, HTLV-2, and/or HCV: A Cross-Sectional, Observational Study.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
03 09 2022
Historique:
received: 16 08 2022
revised: 29 08 2022
accepted: 30 08 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

HIV, HTLV-1/-2, and HCV share routes of transmission, and such virus co-infections could account for worse outcomes of associated diseases. Measuring cytokines/chemokines, CD4 and CD8 T cells, and HIV viral load (VL) in HIV single-infected and co-infected individuals has prognostic value. We analyzed such biomarkers in 129 blood samples of HIV-infected individuals matched for age and sex and divided into six groups (G1 (69 HIV); G2 (9 HIV/HTLV-1); G3 (6 HIV/HTLV-2); G4 (11 HIV/HCV); G5 (19 HIV/HCV/HTLV-1); and G6 (15 HIV/HCV/HTLV-2)). Eight cytokines/chemokines from fifteen analytes could be compared. The highest levels of Th1 and pro-inflammatory cytokines were detected in G2 (IFN-γ) and G6 (IL-6 and IL1-β) and of chemokines in G1 (MIG, IP10, RANTES), G4 (MCP1), and G6 (MIP1-β). The highest CD4 cells number and the lowest HIV VL were identified in G3 and the opposite results in G2. Positive correlations between CD4 and CD8 cells counts and IL-6 levels were detected in G2 and G5 and of HIV VL and RANTES in G4. Negative correlations were detected between CD8 and IFN-γ in G4 and HIV VL and RANTES in G6. Despite the small number of the cohort analyzed, and although the cross-sectional study design does not allow firm conclusions, the homogeneity of the characteristics of HIV/HTLV-co-infected individuals regarding age, time and route of HIV acquisition, and criteria for introducing ART enable us to suggest a negative impact of HTLV-1 and a possible protective role of HTLV-2 in HIV infection progression in such patients.

Identifiants

pubmed: 36146762
pii: v14091955
doi: 10.3390/v14091955
pmc: PMC9501613
pii:
doi:

Substances chimiques

Biomarkers 0
Chemokine CCL5 0
Chemokine CXCL10 0
Interleukin-6 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Transl Med. 2014 Dec 10;12:341
pubmed: 25528160
Science. 1983 May 20;220(4599):868-71
pubmed: 6189183
J Infect Dis. 2016 Aug 1;214(3):408-16
pubmed: 27132283
J Med Virol. 2015 May;87(5):790-7
pubmed: 25678365
J Infect Dis. 2003 Sep 15;188(6):891-7
pubmed: 12964121
PLoS Negl Trop Dis. 2020 May 26;14(5):e0008245
pubmed: 32453768
J Virol. 2009 Apr;83(8):3719-33
pubmed: 19176632
AIDS Rev. 2009 Jan-Mar;11(1):8-16
pubmed: 19290030
Retrovirology. 2005 Mar 02;2:17
pubmed: 15743526
J Infect Dis. 2016 Oct 1;214 Suppl 2:S51-7
pubmed: 27625431
Clin Immunol. 2004 Mar;110(3):252-66
pubmed: 15047203
Braz J Infect Dis. 2018 Mar - Apr;22(2):123-128
pubmed: 29625021
AIDS Res Hum Retroviruses. 2012 Aug;28(8):806-8
pubmed: 22050450
AIDS Res Hum Retroviruses. 2015 May;31(5):543-9
pubmed: 25464979
World J Virol. 2016 May 12;5(2):68-72
pubmed: 27175351
Int J Infect Dis. 2017 Apr;57:116-122
pubmed: 28185943
Blood. 2007 Mar 1;109(5):1850-6
pubmed: 17062725
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):100-6
pubmed: 16340481
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
J Med Virol. 2016 Aug;88(8):1438-47
pubmed: 26800845
J Med Virol. 2016 Nov;88(11):1967-72
pubmed: 27027482
J Int Assoc Provid AIDS Care. 2013 Nov-Dec;12(6):373-4
pubmed: 24222069
J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 3:S202-7
pubmed: 21857319
Viral Immunol. 2012 Aug;25(4):333-7
pubmed: 22788418
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):230-234
pubmed: 29084047
Rev Inst Med Trop Sao Paulo. 2009 Oct-Dec;51(6):325-9
pubmed: 20209267
PLoS Negl Trop Dis. 2013 Jul 25;7(7):e2328
pubmed: 23936564
Cytokine. 2019 Mar;115:97-103
pubmed: 30472104
Scand J Infect Dis. 2010 Dec;42(11-12):896-901
pubmed: 20608766
Rev Soc Bras Med Trop. 2020 Feb 07;53:e20190378
pubmed: 32049201
AIDS Res Hum Retroviruses. 2012 Feb;28(2):139-47
pubmed: 22171689
J Med Virol. 2017 Aug;89(8):1461-1468
pubmed: 28206670
Braz J Infect Dis. 2013 Nov-Dec;17(6):661-6
pubmed: 24029434
Virus Res. 2019 Apr 15;264:40-44
pubmed: 30776394
AIDS Rev. 2007 Jul-Sep;9(3):140-9
pubmed: 17982939
Front Public Health. 2022 Mar 07;10:820727
pubmed: 35359787
J Infect Dis. 2000 Jan;181(1):35-41
pubmed: 10608748
Clin Infect Dis. 2020 Jun 24;71(1):196-200
pubmed: 31406994
J Gerontol A Biol Sci Med Sci. 2008 Aug;63(8):879-84
pubmed: 18772478
Science. 1989 Apr 21;244(4902):359-62
pubmed: 2523562
Mem Inst Oswaldo Cruz. 2018 Feb;113(2):130-134
pubmed: 29236927
Braz J Infect Dis. 2015 Sep-Oct;19(5):486-91
pubmed: 26254690

Auteurs

Adele Caterino-de-Araujo (A)

Laboratório de Pesquisa em HTLV, Centro de Imunologia, Instituto Adolfo Lutz, Av. Dr. Arnaldo 351, 11 Andar, Pacaembu, São Paulo 01246-000, Brazil.

Karoline R Campos (KR)

Laboratório Estratégico, Centro de Respostas Rápidas, Instituto Adolfo Lutz, Av. Dr. Arnaldo 351, 10 Andar, Pacaembu, São Paulo 01246-000, Brazil.

Luanda M S Oliveira (LMS)

Laboratório de Investigação Médica (LIM-56), Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Enéas Carvalho de Aguiar 470, Cerqueira César, São Paulo 05403-000, Brazil.

Paula O Rigato (PO)

Laboratório de Imunologia Celular, Centro de Imunologia, Instituto Adolfo Lutz, Av. Dr. Arnaldo 351, 11 Andar, Pacaembu, São Paulo 01246-000, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH